Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients

AIDS Research and Human Retroviruses

Volumn 29, Issue 12, 2013, Pages 1535-1540

  Boyd, Anders ^a,h   Miailhes, Patrick ^b,c   Brichler, Ségolène ^d,e   Scholtès, Caroline ^b,c   Maylin, Sarah ^f   Delaugerre, Constance ^f   Chevallier Queyron, Phillipe ^b   Gordien, Emmanuel ^d,e   Girard, Pierre Marie ^a,g,h   Lacombe, Karine ^a,g,h  

^a INSERM   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITÉ PARIS 13   (France)

^e INSERM U955   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; TENOFOVIR; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CERVICAL LYMPHADENOPATHY; CLINICAL ARTICLE; DELTA AGENT HEPATITIS; DRUG EFFECT; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF QUANTITATION; LONGITUDINAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SWELLING; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; FEMALE; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HIV; HIV INFECTIONS; HUMANS; INTERFERONS; LIMIT OF DETECTION; MALE; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 84888328122     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0008     Document Type: Article

References (23)

1. Sheng WH, Hung CC, Kao JH, et al.: Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: A matched cohort study. Clin Infect Dis 2007;44(7):988-995.
2. Soriano V, Grint D, d'Arminio Monforte A, et al : Hepatitis delta in HIV-infected individuals in Europe. AIDS 2011;25(16): 1987-1992.
3. Hughes SA, Wedemeyer H, and Harrison PM: Hepatitis delta virus. Lancet 2011;378(9785):73-85.
4. Sheldon J, Ramos B, Toro C, et al.: Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther 2008;13(1):97-102.
5. Maylin S, Boyd A, Lavocat F, et al.: Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIVhepatitis B virus-infected patients. AIDS 2012;26(8):939-949.
6. Babiker ZO, Hogan C, Ustianowski A, and Wilkins E: Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta super-infection? J Med Microbiol 2012;61: 1780-1781.
7. Wedemeyer H, Yurdaydin C, Dalekos GN, et al.: Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364(4):322-331.
8. Yurdaydin C, Wedemeyer H, Caruntu FA, et al.: Pegylatedinterferon-a-2a plus tenofovir or placebo for the treatment of hepatitis delta: First results of the HIDIT-2 study. Hepatology 2012;56(S1):54A.
9. Lutz HH and Trautwein C: Reviving pegylated interferon as a therapeutic agent for hepatitis D: No more room for nucleos( t)ides? Hepatology 2011;53(6):2131-2133.
10. Mansour W, Ducancelle A, Le Gal F, et al.: Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol 2010;47(1):97-99.
11. Kittner JM, Sprinzl MF, Grambihler A, et al.: Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 2012;54(1): 93-95.
12. Lacombe K, Gozlan J, Boelle PY, et al.: Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate. AIDS 2005;19(9): 907-915.
13. Le Gal F, Gordien E, Affolabi D, et al.: Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005;43(5):2363-2369.
14. Scholtes C, Icard V, Amiri M, et al.: Standardized onestep real-time reverse transcription-PCR assay for universal detection and quantification of hepatitis delta virus from clinical samples in the presence of a heterologous internal-control RNA. J Clin Microbiol 2012;50(6):2126-2128.
15. Brichler S, Le Gal F, Neri-Pinto F, et al.: Urgent need for a standardized hepatitis delta virus RNA quantification method: Results of a French National quality control. Paper presented at the Asian Pacific Association for the Study of the Liver Week 2013, 6-10 June, 2013; Singapore.
16. Boursier J, Bacq Y, Halfon P, et al.: Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009; 21(1):28-38.
17. Bedossa P and Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24(2):289-293.
18. Yurdaydin C, Bozkaya H, Onder FO, et al.: Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008;15(4):314-321.
19. Triantos C, Kalafateli M, Nikolopoulou V, and Burroughs A: Meta-analysis: Antiviral treatment for hepatitis D. Aliment Pharmacol Ther 2012;35(6):663-673.
20. Iser DM, Warner N, Revill PA, et al.: Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J Virol 2010;84(12):5860-5867.
21. Miailhes P, Trabaud MA, Pradat P, et al.: Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: Relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007;45(5): 624-632.
22. Manns M, Heidrich B, and Wedemeyer H: Unmet needs in delta hepatitis. Paper presented at the EASL Monothematic Conference on Delta Hepatitis, 22-24 September, 2010; Istanbul, Turkey.
23. Niro GA, Smedile A, Ippolito AM, et al.: Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol 2010;53(5):834-840.